Qiagen: First feedback from Qiagen's Investors Day

BUY, Fair Value Under Review

News published on November Tuesday 19, 2013
Share on

During this Investors Day, a diversified portfolio with significant growth perspectives on QiaSymphony, QuantiFeron TB, Personalised healthcare and Bio-Informatics was promoted. In sequencing, the strategy was detailed with a launch expected to take place in 2014 of Qiagen’s global solution which has the potential to differentiate from the competition in our view. Among highlights from the day is clearly the focus on margins and cash-flow generation as well as the new bonus system for management that has just been implemented. Profit-taking yesterday was the result of rumours about an exit by the second biggest shareholder in the US, unfounded. Should this be reflected in Europe then a comeback at around EUR17 per share would be a good opportunity to reinforce positions in the stock. FV under review.

Full report available to subscribers
Please contact marketing@bryangarnier.fr   

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities